Literature DB >> 9834719

Routine prenatal screening for HIV in a low-prevalence setting.

D M Patrick1, D M Money, J Forbes, S R Dobson, M L Rekart, D A Cook, P J Middleton, D R Burdge.   

Abstract

BACKGROUND: The objectives of this study were to assess the effect of British Columbia's June 1994 guidelines for prenatal HIV screening on the rate of maternal-fetal HIV transmission and to estimate the cost-effectiveness of such screening.
METHODS: The authors conducted a retrospective review of pregnancy and delivery statistics, HIV screening practices, laboratory testing volume, prenatal and labour management decisions of HIV-positive women, maternal-fetal transmission rates and associated costs.
RESULTS: Over 1995 and 1996, 135,681 women were pregnant and 92,645 carried to term. The rate of HIV testing increased from 55% to 76% of pregnancies on chart review at one hospital between November 1995 and November 1996. On the basis of seroprevalence studies, an estimated 50.2 pregnancies and 34.3 (95% confidence interval 17.6 to 51.0) live births to HIV-positive women were expected. Of 42 identified mother-infant pairs with an estimated date of delivery during 1995 or 1996, 25 were known only through screening. Of these 25 cases, there were 10 terminations, 1 spontaneous abortion and 14 cases in which the woman elected to carry the pregnancy to term with antiretroviral therapy. There was one stillbirth. One instance of maternal-fetal HIV transmission occurred among the 13 live births. The net savings attributable to prevented infections among babies carried to term were $165,586, with a saving per prevented case of $75,266.
INTERPRETATION: A routine offer of pregnancy screening for HIV in a low-prevalence setting reduces the rate of maternal-fetal HIV transmission and may rival other widely accepted health care expenditures in terms of cost-effectiveness.

Entities:  

Mesh:

Year:  1998        PMID: 9834719      PMCID: PMC1229739     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  18 in total

1.  Childhood human immunodeficiency virus infection: the spectrum of costs.

Authors:  R H Parrott
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

2.  Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineffectiveness of targeted screening.

Authors:  M B Barbacci; G A Dalabetta; J T Repke; B L Talbot; P Charache; B F Polk; R E Chaisson
Journal:  Sex Transm Dis       Date:  1990 Jul-Sep       Impact factor: 2.830

3.  Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension.

Authors:  J T Edelson; M C Weinstein; A N Tosteson; L Williams; T H Lee; L Goldman
Journal:  JAMA       Date:  1990-01-19       Impact factor: 56.272

4.  Cost-effectiveness analysis of end-stage renal disease treatments.

Authors:  T I Garner; R Dardis
Journal:  Med Care       Date:  1987-01       Impact factor: 2.983

5.  Is screening for breast cancer cost-effective?

Authors:  A I Mushlin; L Fintor
Journal:  Cancer       Date:  1992-04-01       Impact factor: 6.860

6.  Pediatric human immunodeficiency virus infection. Recent evidence on the utilization and costs of health services.

Authors:  D C Hsia; J A Fleishman; J A East; F J Hellinger
Journal:  Arch Pediatr Adolesc Med       Date:  1995-05

7.  Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis.

Authors:  M L Brandeau; D K Owens; C H Sox; R M Wachter
Journal:  Arch Intern Med       Date:  1992-11

8.  Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group.

Authors:  P B Matheson; E J Abrams; P A Thomas; M A Hernán; D M Thea; G Lambert; K Krasinski; M Bamji; M F Rogers; M Heagarty
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

9.  HIV infection among women undergoing abortion in Montreal.

Authors:  R S Remis; E L Eason; R W Palmer; M Najjar; P Leclerc; F Lebel; M Fauvel
Journal:  CMAJ       Date:  1995-11-01       Impact factor: 8.262

10.  Failure to identify human immunodeficiency virus-seropositive newborns: epidemiology and enrollment patterns in a predominantly white, nonurban setting.

Authors:  J Coplan; T D Dye; K A Contello; C K Cunningham; K Kirkwood; L B Weiner
Journal:  Pediatrics       Date:  1995-12       Impact factor: 7.124

View more
  5 in total

1.  Viral screening and assisted conception treatment--the Bourn Hall experience.

Authors:  N Abusheikha; F Akagbosu; S Marcus; A Lass; C Cousins; P Brinsden
Journal:  J Assist Reprod Genet       Date:  1999-07       Impact factor: 3.412

2.  Maternity Care Guidelines checklist. To assist physicians in implementing CPGs.

Authors:  C M Kirkham; S Grzybowski
Journal:  Can Fam Physician       Date:  1999-03       Impact factor: 3.275

Review 3.  Opt in or opt out: what is optimal for prenatal screening for HIV infection?

Authors:  Sharon Walmsley
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

4.  Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices.

Authors:  Mark Downing; Laura Youden; Beth A Halperin; Heather Scott; Bruce Smith; Scott A Halperin
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-07       Impact factor: 2.471

5.  Perinatal HIV transmission and the cost-effectiveness of screening at 14 weeks gestation, at the onset of labour and the rapid testing of infants.

Authors:  Belinda Udeh; Chiedozie Udeh; Nicholas Graves
Journal:  BMC Infect Dis       Date:  2008-12-31       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.